JAZZ vs. QGEN: Jazz Pharmaceuticals vs. Qiagen Stock Comparison
How do Jazz Pharmaceuticals (JAZZ) and Qiagen (QGEN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Jazz Pharmaceuticals (JAZZ) and Qiagen (QGEN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but JAZZ is classified in Pharmaceuticals while QGEN is classified in Life Sciences Tools & Services.
| Profile Item | JAZZ | QGEN |
|---|---|---|
| Name | Jazz Pharmaceuticals plc | Qiagen N.V. |
| Country/Region | Ireland | Netherlands |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Life Sciences Tools & Services |
| GICS Sub-Industry | Pharmaceuticals | Life Sciences Tools & Services |
| Market Capitalization | 15.07 billion USD | 10.39 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | June 1, 2007 | June 28, 1996 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | JAZZ | QGEN |
|---|---|---|
| Total Return (1Y) | 84.44% | 17.09% |
| Total Return (3Y, Annualized) | 27.57% | 10.44% |
| Total Return (5Y, Annualized) | 12.88% | -0.72% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | JAZZ | QGEN |
|---|---|---|
| Volatility (1Y, Annualized) | 38.74% | 35.52% |
| Beta (5Y) | 0.33 | 0.56 |
| Max Drawdown (5Y) | -42.03% | -41.97% |
| Avg. Volume (3M) | 878.80K | 3.68M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | JAZZ | QGEN |
|---|---|---|
| Sharpe Ratio (1Y) | 2.07 | 0.36 |
| Sortino Ratio (1Y) | 4.14 | 0.60 |
Profitability
ROE (TTM)
Qiagen (QGEN) at 10.81% sits in the top ROE quartile, while Jazz Pharmaceuticals (JAZZ) at 5.05% is closer to the peer norm — stronger capital efficiency for QGEN.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.05%
- Max
- 109.18%
- Q3
- 6.23%
- JAZZ
- 5.05%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.81%
- Max
- 109.18%
- QGEN
- 10.81%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Qiagen (QGEN) at 18.20% converts revenue to bottom-line profit above its industry’s benchmark range, while Jazz Pharmaceuticals (JAZZ) at 4.37% keeps roughly the typical share for its industry.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.37%
- Max
- 18.05%
- Q3
- 4.78%
- JAZZ
- 4.37%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.20%
- QGEN
- 18.20%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Jazz Pharmaceuticals (JAZZ) at 30.17% and Qiagen (QGEN) at 27.75% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.17%
- Max
- 83.12%
- JAZZ
- 30.17%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.75%
- Max
- 83.12%
- QGEN
- 27.75%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | JAZZ | QGEN |
|---|---|---|
| ROE (TTM) | 5.05% | 10.81% |
| ROA (TTM) | 6.92% | 5.68% |
| Net Margin (TTM) | 4.37% | 18.20% |
| Operating Margin (TTM) | 30.17% | 27.75% |
| Gross Margin (TTM) | 91.10% | 67.06% |
Growth
Revenue Growth
Both Jazz Pharmaceuticals (JAZZ) at 4.88% and Qiagen (QGEN) at 5.65% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Qiagen (QGEN) at 409.76% delivers above-range EPS growth, while Jazz Pharmaceuticals (JAZZ) at -167.51% falls into the bottom quartile — a wide split in earnings momentum.
Growth Metrics
| Metric | JAZZ | QGEN |
|---|---|---|
| Revenue Growth (YoY) | 4.88% | 5.65% |
| Revenue Growth (3Y CAGR) | 5.26% | -0.81% |
| EPS Growth (YoY) | -167.51% | 409.76% |
| EPS Growth (3Y CAGR) | -- | -0.19% |
Financial Strength
Current Ratio (MRQ)
Qiagen (QGEN) at 2.63 keeps current ratio within its industry’s typical mid-range, while Jazz Pharmaceuticals (JAZZ) at 1.82 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for JAZZ.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.82
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- JAZZ
- 1.82
- Min
- 0.10
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.63
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- QGEN
- 2.63
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Qiagen (QGEN) at 0.47 carries an industry-typical debt-to-equity mix, while Jazz Pharmaceuticals (JAZZ) at 1.35 uses more debt funding than most peers.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 1.42
- JAZZ
- 1.35
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.47
- Max
- 1.42
- Q3
- 0.65
- QGEN
- 0.47
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | JAZZ | QGEN |
|---|---|---|
| Current Ratio (MRQ) | 1.82 | 2.63 |
| Debt / Equity (MRQ) | 1.35 | 0.47 |
| Net Debt / EBITDA | 1.39 | 1.08 |
Dividends
Dividend Yield (TTM)
Jazz Pharmaceuticals (JAZZ) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Qiagen (QGEN) reports a yield of 0.71%, ranking against industry peers normally.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.71%
- QGEN
- 0.71%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Jazz Pharmaceuticals (JAZZ) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Qiagen (QGEN) reports a payout of 18.21%, ranking against industry peers normally.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- JAZZ
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.21%
- QGEN
- 18.21%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | JAZZ | QGEN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.71% |
| Dividend Payout Ratio (TTM) | 0.00% | 18.21% |
Valuation
P/E Ratio (TTM)
Qiagen (QGEN) at 27.21 is near its industry’s usual P/E ratio, while Jazz Pharmaceuticals (JAZZ) at 69.46 sits in the richer quartile — JAZZ needs stronger growth or earnings quality to justify the premium.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
69.46
- Max
- 85.34
- JAZZ
- 69.46
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.21
- Max
- 85.34
- Q3
- 43.46
- QGEN
- 27.21
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Jazz Pharmaceuticals (JAZZ) at 3.19 and Qiagen (QGEN) at 4.91 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.19
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- JAZZ
- 3.19
- Q1
- 3.01
- Min
- 0.01
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.91
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- QGEN
- 4.91
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Jazz Pharmaceuticals (JAZZ) at 3.59 and Qiagen (QGEN) at 2.99 are valued close to their industries’ norm against book — neither stands out from peers.
JAZZ
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.59
- Max
- 13.53
- Q3
- 6.54
- JAZZ
- 3.59
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
QGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.99
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- QGEN
- 2.99
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | JAZZ | QGEN |
|---|---|---|
| P/E Ratio (TTM) | 69.46 | 27.21 |
| P/S Ratio (TTM) | 3.19 | 4.91 |
| P/B Ratio (MRQ) | 3.59 | 2.99 |
| Free Cash Flow Yield (TTM) | 11.16% | 3.62% |